ArticleNuclear medicine and biology2019
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals.
Article in Nuclear medicine and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 55 citations in OpenAlex.
- Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Rapid assessment of target-binding fractions in molecular imaging agents using size-exclusion HPLC.EJNMMI radiopharmacy and chemistry · 2026Article
- A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.Cell · 2026Article
- Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy.Nature biomedical engineering · 2026Article
- Preclinical Evaluation of an Anti-EphA2 Minibody-Based ImmunoPET Agent as a Diagnostic Tool For Cancer.Molecular imaging and biology · 2025Article
- Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody.Bioconjugate chemistry · 2025Article
- IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Imaging PD-L1 in the brain-Journey from the lab to the clinic.Neuro-oncology · 2025Article
- uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Water solubility and folate receptor affinity-driven plasma membrane-targeted carbon dots for cancer cell imaging.RSC advances · 2024Article
- Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a BivalentJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Cadherin-17 as a target for the immunoPET of adenocarcinoma.European journal of nuclear medicine and molecular imaging · 2024Article
- CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Good practices forEJNMMI radiopharmacy and chemistry · 2024Review
- Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- MIB Guides: Measuring the Immunoreactivity of Radioimmunoconjugates.Molecular imaging and biology · 2024Article
- ImmunoPET imaging of TIGIT in the glioma microenvironment.Scientific reports · 2024Article
- CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
introductionDetermination of the target-binding fraction (TBF) of radiopharmaceuticals using cell-based assays is prone to inconsistencies arising from several intrinsic and extrinsic factors. Here, we report a cell-free quantitative method of analysis to determine the TBF of radioligands.
methodsMagnetic beads functionalized with Ni-NTA or streptavidin were incubated with 1 μg of histidine-tagged or biotinylated antigen of choice for 15 min, followed by incubating 1 ng of the radioligand for 30 min. The beads, supernatant and wash fractions were measured for radioactivity on a gamma counter. The TBF was determined by quantifying the percentage of activity associated with the magnetic beads.
resultsThe described method works robustly with a variety of radioisotopes and class of molecules used as radioligands. The entire assay can be completed within 2 h.
conclusionThe described method yields results in a rapid and reliable manner whilst improving and extending the scope of previously described bead-based radioimmunoassays. ADVANCES IN KNOWLEDGE: Using a bead-based radioligand binding assay overcomes the limitations of traditional cell-based assays. The described method is applicable to antibody as well as non-antibody based radioligands and is independent of the effect of target antigen density on cells, the choice of radioisotope used for synthesis of the radioligand and the temperature at which the assay is performed. IMPLICATIONS FOR PATIENT CARE: The bead-based radioligand binding assay is significantly easier to perform and is ideally suited for adoption by the radiopharmacy as a quality control method of analysis to fulfill the criteria for release of radiopharmaceuticals in the clinic. The use of this assay is likely to ensure a more reliable validation of radiopharmaceutical quality and result in fewer failed doses, which could ultimately translate to an efficient release of radiopharmaceuticals for administration to patients in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.